We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 12

Jury finds in favor of botox manufacturer in off-label use trial

  • Edwards Wildman Palmer LLP
  • -
  • USA
  • -
  • May 28 2010

A California jury recently returned a verdict in favor of Allergan, Inc., in a trial involving claims that Allergan’s promotion of an off-label use of its drug Botox caused the death of a pediatric patient suffering from cerebral palsy

Learned intermediary doctrine: Eleventh Circuit upholds summary judgment in favor of manufacturer in lawsuit claiming antidepressant caused suicide

  • Edwards Wildman Palmer LLP
  • -
  • USA
  • -
  • May 28 2010

The 11th Circuit Court of Appeals recently relied upon the learned intermediary doctrine in affirming summary judgment in favor of Smithkline Beecham Corp. (“SBC”) in a lawsuit claiming that the antidepressant Paxil caused the decedent to commit suicide

Chinese drywall HUD and CPSC issue guidance on remediation of Chinese drywall

  • Edwards Wildman Palmer LLP
  • -
  • USA
  • -
  • May 10 2010

On Friday April 2, 2010, the U.S. Department of Housing and Urban Development (HUD) and the U.S. Consumer Product Safety Commission (CPSC) issued “interim remediation guidance” to homeowners impacted by Chinese manufactured drywall

Jury awards $141 million against Pfizer in connection with off-label use of Neurontin

  • Edwards Wildman Palmer LLP
  • -
  • USA
  • -
  • April 7 2010

A federal jury in Boston recently returned a verdict against Pfizer Inc. in connection with claims that Pfizer unlawfully promoted off-label uses of its anti-epilepsy drug Neurontin

Chinese drywall first bellwether trial ongoing

  • Edwards Wildman Palmer LLP
  • -
  • USA
  • -
  • March 9 2010

The first federal trial in the nationwide Chinese drywall controversy began on February 19th, 2010 in New Orleans and is ongoing

Eight Circuit rejects FDA preemption defense raised by generic drug manufacturers

  • Edwards Wildman Palmer LLP
  • -
  • USA
  • -
  • February 10 2010

On November 27, 2009, the United States Court of Appeals for the Eighth Circuit held that failure to warn claims directed at generic pharmaceutical manufacturers are not preempted by federal law

Chinese drywall Consumer Product Safety Commission finds link between corrosion and Chinese manufactured drywall

  • Edwards Wildman Palmer LLP
  • -
  • China, USA
  • -
  • November 24 2009

On Monday November 23, 2009, the Consumer Product Safety Commission ("CPSC") issued a press statement and study results demonstrating a "strong association" between homes with the Chinese manufactured drywall and levels of hydrogen sulfide and corrosion of metals in those homes

Botox maker files First Amendment suit against the FDA

  • Edwards Wildman Palmer LLP
  • -
  • USA
  • -
  • November 3 2009

Allergan, Inc., the maker of the drug Botox, recently filed suit against the Food & Drug Administration, alleging that certain FDA regulations unconstitutionally restrict Allergan’s truthful speech regarding off-label uses of its drug

Delaware court holds that endorsement requires exhaustion of separate retained limits for each lot or batch of contaminated peanut butter

  • Edwards Wildman Palmer LLP
  • -
  • USA
  • -
  • November 2 2009

Stephen Prignano and Denise Kraft, of Edwards Angell Palmer & Dodge, LLP, have obtained summary judgment for Lexington Insurance Company ("Lexington") in an insurance coverage dispute arising out of a salmonella outbreak caused by contaminated peanut butter

New York appellate court: claims against manufacturer of ear protectors

  • Edwards Wildman Palmer LLP
  • -
  • USA
  • -
  • September 29 2009

Earlier this month, a New York appellate court held that claims against the manufacturer of protective devices for ears were barred by the three-year statute of limitations governing actions to recover damages for personal injury